Sandoz signs 10-year agreement with partner Delpharm, a global pharmaceutical developer and contract manufacturerAgreement will secure a reliable ...

Swiss generics and biosimilars giant Sandoz today announced financial results for the full year 2024, showing that sales were ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Skincare product maker Galderma, and pharmaceutical company Sandoz both returned to their home market this week, bringing ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

SteinCares serves as a bridge between pharmaceutical companies ... to market with many biosimilars and generic products, we were selected by Sandoz to do this transaction in Colombia,” he ...

Melbourne: Avecho Biotechnology Limited has announced it has signed an exclusive ten-year development and licensing agreement ...

Avecho Biotechnology (ASX: AVE) has signed a ten-year development and licensing agreement with Sandoz (SWX: SDZ) for the commercial rights to its cannabidiol (CBD) capsule for insomnia in Australia.

TORONTO, Feb. 18, 2025 /CNW/ - The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the unanimous election of Michel Robidoux, President and General Manager at Sandoz ...